Dare Bioscience (DARE) EBITDA (2016 - 2026)
Dare Bioscience's (DARE) quarterly EBITDA came in at -$1.5 million in Q4 2025, up 72.69% YoY from -$851947.8 in Q4 2024, and up 59.93% on a QoQ basis from -$3.7 million in Q3 2025.
Dare Bioscience (DARE) EBITDA (2016 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 10 years of EBITDA data on file, last reported at -$1.5 million in Q4 2025.
- Quarterly EBITDA rose 72.69% year-over-year to -$1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.6 million (up 42.21% YoY) and the FY2025 annual result came in at -$13.6 million, up 42.21% from the prior year.
- EBITDA improved to -$1.5 million in Q4 2025, from -$3.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $384322.0 in Q2 2022 to a low of -$16.2 million in Q4 2022.
- A 5-year average of -$6.9 million and a median of -$7.2 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA surged 104.19% — and 2023, when it slumped 2439.02%.
- Tracing DARE's EBITDA over 5 years: stood at -$9.5 million in 2021, then plunged by 70.08% to -$16.2 million in 2022, then soared by 68.14% to -$5.2 million in 2023, then slipped by 4.19% to -$5.4 million in 2024, then jumped by 72.69% to -$1.5 million in 2025.
- The last three EBITDA figures came in at -$1.5 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Dare Bioscience | 11.91 Mn | -705,728.22 | -132,343.00 | -2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.97 Mn |
| Dec 31, 2025 | -1.47 Mn |
| Sep 30, 2025 | -3.67 Mn |
| Jun 30, 2025 | -3.83 Mn |
| Mar 31, 2025 | -4.58 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Sep 30, 2024 | -4.68 Mn |
| Jun 30, 2024 | -7.36 Mn |
| Mar 31, 2024 | -6.02 Mn |
| Dec 31, 2023 | -5.17 Mn |
| Sep 30, 2023 | -8.40 Mn |
| Jun 30, 2023 | -8.99 Mn |
| Mar 31, 2023 | -8.38 Mn |
| Dec 31, 2022 | -16.23 Mn |
| Sep 30, 2022 | -7.14 Mn |
| Jun 30, 2022 | 384,322.00 |
| Mar 31, 2022 | -8.40 Mn |
| Dec 31, 2021 | -9.54 Mn |
| Sep 30, 2021 | -12.67 Mn |
| Jun 30, 2021 | -9.16 Mn |